Effectiveness and costs of flupentixol compared to other first- and second-generation antipsychotics in the treatment of schizophrenia

Stargardt, Tom, Mavrogiorgou, Paraskevi, Gericke, Christian A. and Juckel, Georg (2011) Effectiveness and costs of flupentixol compared to other first- and second-generation antipsychotics in the treatment of schizophrenia. Psychopharmacology, 216 4: 579-587. doi:10.1007/s00213-011-2256-x


Author Stargardt, Tom
Mavrogiorgou, Paraskevi
Gericke, Christian A.
Juckel, Georg
Title Effectiveness and costs of flupentixol compared to other first- and second-generation antipsychotics in the treatment of schizophrenia
Journal name Psychopharmacology   Check publisher's open access policy
ISSN 0033-3158
1432-2072
Publication date 2011-08-01
Sub-type Article (original research)
DOI 10.1007/s00213-011-2256-x
Open Access Status
Volume 216
Issue 4
Start page 579
End page 587
Total pages 9
Place of publication Heidelberg Germany
Publisher Springer
Language eng
Formatted abstract
Rationale
The purpose of this study is to analyse the effectiveness of flupentixol compared to other first- and second-generation antipsychotics for the treatment of schizophrenia in routine care.

Method
A retrospective cohort study was conducted using administrative data from four sickness funds covering 12.6 million insured. Patients discharged from hospital in 2003 with an ICD-10 diagnosis of schizophrenia were followed for 12 months. Rehospitalisation during follow-up was analysed using a hurdle regression model. Treatment costs were defined as cost of pharmaceutical and cost of inpatient care. Two thousand eight hundred ninety insured were included, of which 177 were treated with flupentixol during follow-up, while 429 and 2,284 were treated with other first-and second-generation antipsychotics, respectively.

Results
Compared to patients treated with flupentixol (21.0 days), predicted hospitalisation did not differ significantly for patients treated with other first- (21.3 days, p = 0.8313) or second-generation antipsychotics (25.6 days, p = 0.4035). Predicted treatment costs for the average patient were 4,193 € if treated with flupentixol, 4,846 € if treated with other first-generation antipsychotic, and 6,523 € if treated with a second-generation antipsychotic. Second-generation antipsychotics showed a clear advantage over flupentixol concerning extrapyramidal symptoms co-medication.

Conclusion
The effectiveness of flupentixol preventing relapse in patients with schizophrenia appears to be similar to that of other first- and second-generation antipsychotics. However, the low treatment costs for patients treated with flupentixol could be explained by the small number of patients with readmissions (70 insured) and the larger share of patients treated with its depot formulation.
Keyword Flupentixol
Atypical antipsychotics
Schizophrenia
Quality-of-life
Randomized controlled-trial
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status Non-UQ

Document type: Journal Article
Sub-type: Article (original research)
Collection: School of Public Health Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 4 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 4 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Sat, 16 Nov 2013, 00:53:42 EST by System User on behalf of School of Public Health